President Trump seeks to honor his campaign promise of lower U.S. medical costs by forcing higher big-pharma prices in foreign countries.

Charlene Vos

2018-05-07 07:32:00 Mon ET

President Trump seeks to honor his campaign promise of lower U.S. medical costs by forcing higher big-pharma prices in foreign countries such as Canada, Britain, France, Germany, Japan, and South Korea. As of early-2018, the typical American spends more than $1,100 on prescription drugs per year.

It is true that many Americans take pills on a regular basis, but what sets the U.S. apart from most other OECD countries relates to high drug prices. President Trump now attempts to induce large pharmaceutical companies such as Merck, Johnson & Johnson, Pfizer, Amgen, and GSK etc to increase their medicine prices abroad. This strategic move would create economic incentives for these companies to cut drug prices in America. In light of the high health insurance and medical costs in America, the Trump administration either has to foster competition among biotech firms and pharmaceutical companies, or the Trump administration needs to induce them to voluntarily reduce medicine prices.

President Trump sometimes retorts with the deliberate hyperbole that drugmakers can **get away with murder** in what they charge the government for medication. As the American population enjoys longer human longevity with better medical technology, lower medicine prices seem to have become a necessary evil for big pharma.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Blue-ocean strategists shift focus from current competitors to alternative non-customers with new market space.

Apple Boston

2020-05-21 11:30:00 Thursday ET

Blue-ocean strategists shift focus from current competitors to alternative non-customers with new market space.

Most blue-ocean strategists shift fundamental focus from current competitors to alternative non-customers with new market space. W. Chan Kim and Renee Ma

+See More

Our proprietary alpha investment model outperforms most stock market indices such as S&P 500, Dow Jones, and Nasdaq.

Andy Yeh Alpha

2019-02-01 15:35:00 Friday ET

Our proprietary alpha investment model outperforms most stock market indices such as S&P 500, Dow Jones, and Nasdaq.

Our proprietary alpha investment model outperforms the major stock market benchmarks such as S&P 500, MSCI, Dow Jones, and Nasdaq. We implem

+See More

Snap cannot keep up with the Kardashians because its stock loses $1 billion market value after Kylie Jenner tweets about her decision to leave Snapchat.

Monica McNeil

2018-02-19 08:39:00 Monday ET

Snap cannot keep up with the Kardashians because its stock loses $1 billion market value after Kylie Jenner tweets about her decision to leave Snapchat.

Snap cannot keep up with the Kardashians because its stock loses market value 7% or $1 billion after Kylie Jenner tweets about her decision to leave Snapcha

+See More

Addendum on USPTO fintech patent protection and accreditation

Andy Yeh Alpha

2023-01-11 09:26:00 Wednesday ET

Addendum on USPTO fintech patent protection and accreditation

Addendum on USPTO fintech patent protection and accreditation As of early-January 2023, the U.S. Patent and Trademark Office (USPTO) has approved our U.S

+See More

Pinterest files a $12 billion IPO due in mid-2019.

Laura Hermes

2019-03-09 12:43:00 Saturday ET

Pinterest files a $12 billion IPO due in mid-2019.

Pinterest files a $12 billion IPO due in mid-2019. This tech unicorn allows users to pin-and-browse images through its social media app and website. Pintere

+See More

What is our asset management strategy?

Andy Yeh Alpha

2026-02-28 10:29:00 Saturday ET

What is our asset management strategy?

AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors. As of March 2026, we have up

+See More